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Abstract
Background: Hepatocellular carcinoma (HCC) exhibits strong intrinsic and acquired drug resistance which is the
main obstacle to chemotherapy. Overexpression of ATP binding cassette (ABC) proteins correlates with activation of
mitogen activated protein kinase (MAPK) pathway in HCC. Here, we systematically investigated the inhibition of
MAPK pathway and its role in regulating HCC cell growth as well as ABC proteins MRP1 and MRP3 expression.
Methods: The Raf1 kinase inhibitor (GW5074) and different MEK inhibitors (U0126 and AZD6244) were used to treat
HCC cells to identify their effects on HCC cell growth and ABC proteins expression in vitro. Cell viability tests were
performed after the treatment of MAPK pathway inhibitors and in combination with gemcitabine or doxorubicin.
Western blot was applied to assess the changes of MAPK pathway and protein expression of MRP1 and MRP3. Flow
cytometry was used to measure intracellular doxorubicin accumulation after the treatment of MEK inhibitors.
Results: Both Raf1 inhibitor (GW5074) and MEK inhibitors (U0126 and AZD6244) suppressed HCC cell growth in a
dose dependent manner. Pre-treatment of MEK inhibitor U0126 or AZD6244 sensitized HCC cells to gemcitabine or
doxorubicin based chemotherapy. Raf1 inhibitor GW5074 had no effect on MRP1 and MRP3 protein expression.
Treatment of gemcitabine or doxorubicin activated phosphorylated ERK and induced the upregulation of MRP1 and
MRP3. MEK inhibitors U0126 and AZD6244 deactivated phosphorylated ERK, decreased endogenous MRP1
expression, reversed gemcitabine or doxorubicin induced MRP1 and MRP3 upregulation, and increased the
intracellular doxorubicin accumulation.
Conclusion: This study provides evidence that MEK inhibitors sensitize HCC cells to chemotherapy by increasing
intracellular chemodrug accumulation. MEK inhibirors U0126 and AZD6244 reduced MRP1 as well as MRP3
expression, and may contribute partially to the sensitization. The combination of MEK inhibitor and conventional
chemotherapy may offer new therapeutic option for the treatment of resistant HCC.
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Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer mortality and causes more than half a
million deaths annually worldwide [1,2]. The number of
new cases of primary liver cancer increases globally and
HCC accounts for 70% to 85% of them [3]. Potentially
curative treatment, including liver resection, transplantation
and local ablation, could provide promising 5-year-survival
rate up to 75% [4], however, less than 20% of HCC patients
are eligible for these treatment [5]. For patients who have
either recurrent disease after surgical therapy or initially
advanced HCC, sorafenib is considered to be the first-line
treatment [6]. However, the response to sorafenib treatment
is still low (2%) [7,8]. Furthermore, chemotherapeutic
options for HCC are limited. Systemic chemotherapy with
doxorubicin, gemcitabine or combined regiments for pallia-
tive strategy was reported to provide only marginal effect
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on survival of HCC patients [9-11]. A high intrinsic and
acquired drug resistance in HCC is mainly responsible for
this failure of the systemic chemotherapy [12].
The mechanisms of drug resistance in tumour cells are
heterogeneous, including increased efflux of anticancer
agents by ABC proteins, blocked apoptosis, activated
DNA repair and enhanced detoxifying systems [13].
Among them, ABC proteins contribute to the major form
of drug resistance by increasing the efflux of anticancer
drugs out of cancer cells [14]. Our previous analysis
revealed that, among these ABC proteins, MRP1 and
MRP3 were overexpressed in HCC tissue and may con-
tribute to the high intrinsic drug resistance [15]. We also
previously demonstrated that the phenotype of acquired
drug resistance could be induced by conventional antican-
cer agents in HCC cells. Treatment of gemcitabine and
doxorubicin to HCC cells resulted in an upregulation of
MRP1 and MRP3 gene and protein expression [16].
Thus, inhibition of MRP1 and MRP3 might reverse
multidrug resistance and improve chemotherapeutic
efficiency in HCC.
Overexpression and abnormal activation of the MAPK
pathway were previously detected and correlated statisti-
cally with MRP1 overexpression in HCC tissue [15,17-19].
ERK activation induced by chemotherapy was observed in
HCC cells [16]. Furthermore, Zhang et al. shown that the
basal level of the phosphorylated ERK in HCC cells affected
their chemosensitivity to 5-fluorouracil treatment [20].
These results suggested that MAPK pathway and drug re-
sistance may interact with each other in HCC. Modulation
of ABC proteins expression with tyrosine kinase inhibitors
was proven to be feasible. In HCC, Hoffmann et al.
reported that both gefitinib and sorafenib decreased gem-
citabine and doxorubicin induced upregulation of ABC
proteins and restored the chemosensitivity [16,21]. These
reversal effects originated from inhibition at the receptor
level of the tyrosine kinase pathway. However, the involve-
ment of the downstream MAPK pathway, such as Raf1
and MEK, in mediating the ABC proteins expression
remains unclear in HCC.
The objective of this investigation was to elucidate the
interaction between two key kinases within the MAPK
pathway (Raf1 and MEK) and ABC proteins expression
in HCC. Highly selective inhibitors which inhibited the
Raf1 kinase (GW5074) and the MEK activity (U0126 and
AZD6244) were applied to identify their effects on the
MRP1 and MRP3 protein expression.
Results
GW5074 inhibited HCC cell growth and Raf1 expression
To determine the role of Raf1 inhibition on HCC cell
growth and drug resistance, HCC cells were treated with
the Raf1 kinase inhibitor GW5074 (5 μM–20 μM).
GW5074 exhibited a dose-dependent cell growth inhibition
in HepG2 and Huh7 cells (Figure 1A). We further exam-
ined the effects of GW5074 on MAPK pathway and protein
expression of MRP1 and MRP3 in HCC cells. Western blot
analysis revealed that GW5074 dose-dependently downre-
gulated Raf1 but also increased phosphorylation of Raf1
(Figure 1B). GW5074 activated p-MEK at the concentration
of 5 μM, but the activation declined as the concentration
increased. Furthermore, we showed that GW5074 had no
effect on MRP1 and MRP3 protein expression in both
HCC cell lines (Figure 1B). As shown in Figure 1B, Raf1
inhibition by GW5074 did not exert an inhibitory effect on
p-MEK and p-ERK, but activate the p-MEK. It was
reported that heterodimerization of B-Raf with Raf1
induced by Raf kinase inhibitor GW5074 contributed to
the activation of the downstream MAPK signalling in cells
with mutant k-ras or wild-type B-Raf, such as HepG2
[22,23]. This result indicated Raf1 as the first downstream
of the MAPK pathway is involved in mediating HCC cell
growth, but plays no significant role in the regulation of
MRP1 and MRP3 expression. Thus, it was of interest to
know whether downstream of the Raf1 kinase pathway,
such as MEK or ERK, was involved in mediating MRP1
and MRP3 expression.
MEK inhibitors inhibited HCC cell growth and enhanced
chemosensitivity
To determine whether MEK inhibition could influence
HCC cell growth, HCC cells were treated with the MEK
inhibitor U0126 (5 μm–20 μM) or AZD6244 (5 μm–20
μM) for 48 hours. Both U0126 and AZD6244 exerted
dose-dependent inhibition on HepG2 and Huh7 cell
growth (Figure 2A). These results indicated that down-
stream of MAPK pathway was involved in regulating
HCC cell growth.
We next investigated whether MEK inhibitors could
enhance chemotherapeutic effects. HCC cells were
pretreated with U0126 (10 μM) or AZD6244 (10 μM)
for 24 hours, followed by different concentrations of
gemcitabine or doxorubicin for another 48 hours. As
shown in Figure 2B, the pretreatment of U0126 and
AZD6244 synergistically sensitized HepG2 cells to gemcita-
bine and doxorubicin induced growth inhibition. U0126
also synergistically enhanced the chemosensitivity of doxo-
rubicin in Huh7 cells. Similar synergistic effect of growth
inhibition was observed when Huh7 cells were pretreated
with AZD6244 followed by gemcitabine. However, U0126
did not exert synergistic effect on gemcitabine induced
Huh7 cell growth inhibition. And AZD6244 did not
sensitize the chemotherapeutic effect of doxorubicin in
Huh7 cells, either.
MEK inhibitors reversed MRP1 and MRP3 expression
Western blot analysis revealed that MEK inhibitors
U0126 and AZD6244 modulated the MAPK pathway by
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increasing the p-MEK levels and decreasing the p-ERK
levels. An inhibition of endogenous MRP1 expression was
observed in a dose-dependent manner after 48 hours of
U0126 or AZD6244 treatment (Figure 3A and 3B). Both
U0126 and AZD6244 exerted downregulatory effect on
endogenous MRP3 expression in HepG2 cells. U0126
decreased MRP3 expression at the concentration of 20 μM;
however, AZD6244 dose-dependently increased MRP3
expression in Huh7 cells.
We next examined whether MEK inhibitors had similar
effects on chemotherapy induced upregulation of MRP1
and MRP3. HCC cells were exposed to gemcitabine or
doxorubicin for 48 hours, followed by U0126 or AZD6244
for another 24 hours. Activation of the MAPK pathway
(increased p-ERK) and an upregulation of MRP1 and
MRP3 protein were observed after doxorubicin or gemcita-
bine treatment in both cell lines (Figure 3C and 3D). How-
ever, MEK inhibitors U0126 and AZD6244 reversed the
upregulation of p-ERK as well as MRP1 and MRP3. These
results suggested that MEK kinase was involved in regulat-
ing endogenous as well as chemotherapy induced MRP1
and MRP3 protein expression in HCC cell lines.
U0126 and AZD 6244 increased intracellular doxorubicin
accumulation
Based on enhanced chemosensivity to doxorubicin and
decreased MRP1 expression induced by MEK inhibitors in
HepG2 cells, we hypothesized that MEK inhibitors might
Figure 1 Role of GW5074 on HCC cell growth and ABC proteins expression. A: HepG2 and Huh7 were treated with three different
concentrations (5 μM, 10 μM and 20 μM) of Raf1 kinase inhibitor GW5074. After 48 hours treatment, cell viability test was performed to measure
the relative viability. * P<0.05 compared with control group. B: HepG2 and Huh7 cells were treated with three different concentrations (5 μM, 10
μM and 20 μM) of GW5074 for 48 hours, and then cells were lysed and western blot was performed.
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increase intracellular accumulation of doxorubicin by de-
creasing ABC proteins efflux ability. To confirm this,
FACS analysis was performed to measure doxorubicin
accumulation after U0126 or AZD6244 treatment
(Figure 4A). In HepG2 cells, we observed that the dens-
ity of intracellular doxorubicin fluoresces increased by
46.5% after U0126 treatment and 42.0% after AZD6244
treatment (Figure 4B). In Huh7 cells, U0126 and
AZD6244 treatment exerted 27.4% and 21.8% increase
of intracellular doxorubicin accumulation, respectively
(Figure 4B). These results suggested that MEK inhibitors
increased intracellular accumulation of chemodrug.
Discussion
Hepatocellular carcinoma exhibits its high intrinsic
multidrug resistance (MDR) phenotype through overex-
pression of MRP1 and MRP3, which hampers successful
chemotherapeutic treatment [24,25]. Thus, modulation
of these overexpressed ABC proteins may diversify the
therapeutic choices for HCC. In present study, we inves-
tigated the effects of downstream MAPK pathway (Raf1
and MEK) inhibition on chemosensitivity as well as
MRP1 and MRP3 expression in HCC. We demonstrated
that MEK inhibition sensitized HCC cells to gemcita-
bine and doxorubicin. And we further indicated that
Figure 2 AZD6244 inhibited HCC cell growth and enhanced chemosensitivity. A: HepG2 and Huh7 were treated with four different
concentrations (5 μM, 10 μM, 15 μM and 20 μM) of MEK inhibitor U0126 and AZD6244. After 48 hours treatment, cell viability test was performed
to measure the relative viability. * P<0.05 compared with control group. B: HepG2 and Huh7 cells were treated with U0126 (10 μM) and AZD6244
(10 μM) for 24 hours, followed by gemcitabine (50 μg/ml, 100 μg/ml, 150 μg/ml and 200 μg/ml) or doxorubicin (0.15 μg/ml, 0.30 μg/ml, 0.45 μg/ml
and 0.6 μg/ml) for another 48 hours. Cell viability test was performed to measure the relative viability. *: synergistic effect was detected.
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downregulation of MRP1 and MRP3 by MEK inhibitors
might contribute partially to this sensitization.
Sustained cell proliferation is one of the main features
of cancer [26] and MAPK pathway is involved in regulat-
ing cell proliferation [27]. Raf1 or MEK inhibitor was
reported to suppress HCC cells growth [28-30]. Further-
more, combination of MEK inhibitor (AZD6244) and
doxorubicin lead to synergistic HCC tumor growth inhib-
ition in mouse models [31]. In line with previous investi-
gations, our data showed that monotherapy of either Raf1
inhibitor (GW5074) or MEK inhibitors (U0126 and
AZD6244) exhibited a dose-dependent growth inhibition
of HCC cells. Furthermore, we observed that pretreatment
of MEK inhibitors sensitized HCC cells to doxorubicin or
gemcitabine, and increased intracellular doxorubicin accu-
mulation. Based on these results, we hypothesized that
this additional cell growth inhibition might originate from
increased accumulation of chemotherapeutic reagents in
cancer cells. AZD6244, also known as Selumetinib or
ARRY-142886, has already been tested in phase II clinical
trial for hepatocellular carcinoma which indicated that
AZD6244 had minimal single-agent activity despite
evidence of suppression of target activation [32]. Our
results suggested that combination of AZD6244 with con-
ventional anticancer drugs may be an optional therapeutic
choice.
The aim for the modulation of ABC proteins is to im-
prove the efficacy of anticancer drugs through increasing
intracellular anticancer drug accumulation [33]. Abundant
evidence has shown that tyrosine kinase inhibitors (TKIs)
could modulate ABC proteins either in function or in
mRNA and protein level. Dohse et al. reported that imati-
nib and dasatinib, which inhibit BCR-ABL tyrosine kinase,
could overcome ABCG1 and ABCG2 transporting function
[34]. Similar results were obtained from vandetanib
(VEGFR and EGFR inhibitor) through functional inhibition
of ABCB1, ABCC1 and ABCG2 [35,36]. And U0126 (MEK
inhibitor) promoted PGP protein degradation in colorectal
cancer was also reported [35]. Previous studies in our group
indicated that gefitinib (EGFR inhibitor) and sorafenib
(VEGFR, PDGFR-h and Raf inhibitor) exerted inhibitory
effects on mRNA expression of ABCB1, ABCC1, ABCC2
and ABCC3 [16,21]. Our current results indicated that
MEK inhibitors decreased the endogenous MRP1 protein
Figure 3 MEK inhibitors reversed MRP1 and MRP3 expression. A: HepG2 and Huh7 were treated with four different concentrations (2.5 μM,
5 μM, 10 μM and 20 μM) of U0126. After 48 hours of U0126 treatment, the cells were lysed and western blot was performed. B: HepG2 and Huh7
were treated with four different concentrations (1 μM, 2 μM, 5 μM and 10 μM) of AZD6244. After 48 hours treatment, the cells were lysed and
western blot was performed. C: HepG2 and Huh7 were treated with gemcitabine (114 μg/ml) or doxorubicin (0.6 μg/ml) for 48 hours, and
followed by another 24 hours of U0126 (10 μM) treatment. Then the cells were lysed and western blot was performed. D: HepG2 and Huh7 were
treated with gemcitabine (114 μg/ml) or doxorubicin (0.6 μg/ml) for 48 hours, and followed by another 48 hours of AZD6244 (5 μM) treatment.
Then cells were lysed and western blot was performed.
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Figure 4 U0126 and AZD6244 increased intracellular doxorubicin accumulation. A: HepG2 or Huh7 cells were treated with U0126 or
AZD6244 for 48 hours, followed by incubation of doxorubicin (6 μg/ml) for 2 hours. Then the cells were trypsinized and resuspended in PBS
followed by FACS analysis. B: Statistical analysis of FACS results. * P<0.05 compared with control group.
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expression, which contributed to intrinsic drug resistance
in HCC [25]. As previously reported, acquired drug resist-
ance could be induced by short time chemotherapy, but last
for more than 6 weeks [37]. In HCC, conventional chemo-
therapy enabled cancer cells to acquire drug resistance
through overexpression of MRP1 and MRP3. However,
MEK inhibitors significantly reversed the upregulation of
MRP1 and MRP3 induced by gemcitabine and doxorubicin.
Based on these data, we speculate that MEK inhibitors
might reverse both intrinsic and acquired drug resistance in
HCC cells through inhibition of MRP1 and MRP3 protein
expression.
In contrast to the down-regulation of MRP1 and MRP3
protein expression, mRNA expression was increased after
the U0126 treatment, especially for MRP3 (data not
shown). Furthermore, U0126 also exerted an enhancive ef-
fect on ABCC3 mRNA upregulation induced by gemcita-
bine and doxorubicin, while MRP3 protein expression was
decreased after U0126 treatment. Dreuw et al. also reported
similar results, namely that exposure of U0126 to dermal
fibroblasts enhanced ABCC3 mRNA expression [38]. The
post transcriptional regulation may well be responsible for
this phenomenon. By using pulse chase experiments,
Katayama et al. reported that U0126 promoted PGP deg-
radation but did not affect its biosynthesis [35]. Moreover,
it was reported that MEK inhibitor could induce tran-
scriptional upregulation of endogenous BCRP through the
inhibition of the MEK-ERK-RSK pathway, but promote
post-transcriptional protein degradation of endogenous
BCRP through the inhibition of the MEK-ERK-non-RSK
pathway in breast cancer cells [39]. Further experiments
indicated that the 5’ end of the ABCB1 mRNA in normal
colon cancer cells was shorter than in doxorubicin resist-
ant breast cancer cells, and alternative promoters were
responsible for the PGP post-transcriptional regulation,
which exhibited increased ABCB1 mRNA expression
but unchanged protein expression and PGP efflux func-
tion [40]. However, the mechanisms involved in post-
transcriptional degradation of MRP1 and MRP3 require
further elucidation.
MEK inhibitor exerted stronger downregulatory effect on
the endogenous MRP1 expression than MRP3. The MRP1
expression is very low or even could not be detected in
healthy human hepatocytes [41]. Significant inhibition of
MRP1 expression and unchanged endogenous MRP3 ex-
pression would not result in severe physiological disorders
of hepatocytes. This difference may be of great importance
especially to the HCC patients with decompensated liver
function who would usually get no therapy.
Extensive evidence has shown that the EGF-Ras-MAPK
pathway was involved in the regulation of ABC protein
expression. EGF stimulation activated MAPK pathway,
furthermore, enhanced the PGP expression, and promoted
the ABCC1, ABCC2 as well as ABCC3 gene expression
[16,42-44]. We previously reported that EGFR inhibition
suppressed ABCB1, ABCC1, ABCC2 and ABCC3 mRNA
expression [16]. Moreover, ERK siRNA decreased PGP
expression was also demonstrated [35]. Here, we identified
that downstream of the EGF pathway, MEK might be
another target for reversing MRP1 and MRP3 expression.
Based on these results, we hypothesized the involvement
of the EGF pathway in the regulation of ABC protein
expression as shown in Figure 5.
Conclusions
Our results provide the evidence that the MAPK pathway
is not only involved in the regulation of HCC cell prolifera-
tion but also may be involved in the regulation of multidrug
resistance. For the first time, we systemically revealed that
the inhibition of MEK with the MEK inhibitors U0126 or
AZD6244 could lead to a downregulation of MRP1 and
MRP3 expression in HCC in vitro. MEK inhibition might
be a novel therapeutic option to reverse multidrug resist-
ance in HCC patients.
Materials and methods
Cell lines and materials
Two human hepatocellular carcinoma cell lines (HepG2
and Huh7) were used for the in vitro experiments:
HepG2 was purchased from Toni Lindl GmbH (Munich,
Germany); Huh7 was a gift from Prof. Herr (Division
of Molecular OncoSurgery, Ruprecht-Karls-University,
Heidelberg, Germany). HepG2 cells were cultured in
RPMI 1640 medium (Life Technologies, Gaithersburg,
USA) containing 10% fetal bovine serum (FBS), 100 UI/ml
penicillin and 100 μg/ml streptomycin (Biochrom AG,
Berlin, Germany). Huh7 cells were cultured in Dulbecco's
modified Eagle medium (DMEM) (Life Technologies,
Gaithersburg, USA) with 10% FBS, 100 UI/ml penicillin
and 100 μg/ml streptomycin. Cells were maintained at 37°C
and in 5% CO2.
Gemcitabine (Lilly, Indianapolis, USA) and doxorubicin
(Sandoz Pharmaceuticals GmbH, Holzkirchen, Germany)
were dissolved in medium. The Raf1 inhibitor GW5074
and MEK inhibitor U0126 were purchased from
Calbiochem (Darmstadt, Germany). MEK inhibitor
AZD6244 was purchased from OTAVA (Toronto,
Canada). Inhibitors were dissolved in DMSO and 0.1%
DMSO (V/V) or 0.2% DMSO (V/V) was used as vehicle
control.
Cell viability test
HCC cells were seeded in 96-well-plate containing 100 μl
medium at a density of 4,000 cells per well. After 48 hours
incubation, cells were treated. Then the medium was
discarded carefully and the cells were stained with crystal
violet (0.2 g crystal violet dye, 2 ml ethanol in 98 ml
distilled water) for 15 min. The crystal violet was
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discarded, and the wells were washed with distilled water
twice and then dried. Then 200 μl straight methanol was
added into each well. The optical density was read at
570 nm by Biochrom Anthos 2010 microplate reader
(Biochrom LTD. Cambridge, UK). Cell viability test
were done in triplicate and three independent experi-
ments were performed. Additive effect of MEK inhibitor
and chemodrugs was analysed by Bliss independence
model of additivity. The fractional response to drug A
alone is Fa, and the fracitonal response of drug B alone
is Fb. If the total response to a mixture of the two drugs
is more than Fa+Fb-Fa*Fb, it can be assumed that these
two drugs are additive.
Western blot
Cells were lysed with RIPA buffer (Sigma Aldrich, Munich,
Germany) for 10 min on ice. Then the lysates were cen-
trifuged for 15 min at 4°C with the speed of 16,100 rcf.
After that, the supernatant was collected and protein
concentration was determined by BCA method using
BCA™ Protein Assay Kit (Thermo Scientific, Rockford,
USA). ×20 μg of whole cell extracts were heated with
LDS sample buffer (Invitrogen, Carlsbad, USA) at 70°C
for 10 min. Then the protein was separated by SDS-
PAGE in 4-12% Bis-Tris gel (Invitrogen, Carlsbad, USA)
and transferred to the Pure Nitrocellulose Membrane
(BIO-RAD, California, USA). After blocking for one
hour, the membrane was incubated with primary anti-
bodies at 4°C overnight. Then the membrane was probed
with horseradish-peroxidase conjugated secondary anti-
body (Santa Cruz, Heidelberg, Germany) for one hour at
room temperature. The bands were visualised by West
PICO Chemiluminescent substrate (Thermo Scientific,
Rockford, USA) and photographed by image acquisition
system (Vilber, Eberhardzell, Germany). The band density
was analysed by ImageJ and the relative expression of
MRP1 and MRP3 were calibrated by the actin.
The antibodies for western blot were purchased from:
Actin (A1978) (Sigma Aldrich, Steinheim, Germany);
p-ERK (#4377), p-MEK (#9121), MEK (#4694), p-Raf1
(#9427), and Raf1 (#9422) (Cell Signaling, Frankfurt,
Germany); MRP3 (sc-20767), ERK (sc-135900), and the
secondary antibodies goat anti rabbit (sc-2004) as well
as goat anti mouse (sc-2005) (Santa Cruz, Heidelberg,
Germany); MRP1 (ab32574) (Abcam, Cambridge, UK).
Intracellular doxorubicin accumulation
Intracellular doxorubicin accumulation was measured by
flow cytometry (FACS) analysis. HepG2 or Huh7 cells
were seeded and cultured in 10 cm plates for 48 hours.
Then cells were treated with U0126 or AZD6244 for
another 48 hours. After the treatment, the cells were
washed with PBS, and incubated with doxorubicin
(6 μg/ml) for 2 hours. Then the cells were trypsinized
Figure 5 Hypothesized mechanism of involvement of the EGF pathway in the regulation of ABC protein expression.
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and resuspended in PBS followed by FACS analysis with
BD FACScan System (Becton Dickinson, New Jersey, USA).
The red fluorescence for doxorubicin in FL2 channel
(Exmax 496 nm/Emmax 578 nm) was used. 50, 000 cells were
collected. The data was analysed by FlowJo 7.6.2 (Treestar,
Ohio, USA).
Statistics
The results were presented as mean values ± standard
deviation (SD). And difference was determined by using
one-way analysis of variance (ANOVA) test followed by
Student-Newman-Keuls test. The statistical significance
was defined as P<0.05. All statistical analysis was per-
formed by SigmaStat 2.03 (Jandel Scientific, San Rafael,
CA, USA).
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